-
Drugmakers long ceased to be the only villain of the insulin price scandal. While Lilly is cutting the list price” and others may follow, will other "parties" (i.e. pharmacy benefit managers) cause this price to increase before it hits the pharmacy counter?
-
The billionaire entrepreneur, Dallas Mavericks owner and "Shark Tank" star is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
-
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
-
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
-
Perspective: Amid skyrocketing drug prices, it’s understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our health care system’s reckless spending.
-
A diabetes diagnosis is not always related to a person’s weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
-
Drug manufacturers invested in Russia’s pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion.
-
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars — and cutting back services to patients — as a result.
-
The pharmaceutical and medical device business will keep the J&J name while the division that sells Band-Aids and Listerine will go it alone.
-
Judge Colleen McMahon was expected to halt work on the controversial settlement that would give immunity from opioid lawsuits to the Sackler family. Instead she allowed work on the plan to go ahead.